TY - JOUR T1 - Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres JF - Clinical Medicine JO - Clin Med SP - 201 LP - 204 DO - 10.7861/clinmedicine.19-3-201 VL - 19 IS - 3 AU - Claire Bethune AU - Richard Herriot Y1 - 2019/05/01 UR - http://www.rcpjournals.org/content/19/3/201.abstract N2 - The use of regular infusions of immunoglobulin is well established as a treatment for patients with antibody deficiency and for patients requiring immunomodulation. Although efficacy is believed to be equivalent for the different immunoglobulin products, it is generally regarded as best practice not to switch from one product to another unless there is a clinical reason to change. Changes in commissioning guidance and issues with the supply of some immunoglobulin products to the UK resulted in a requirement for a significant number of patients to switch between immunoglobulin products in 2017–2018. Data from the 2018 UK Primary Immunodeficiency census has been used to evaluate the clinical results of switching. Results from 30 immunology centres reported a total of 802 immunoglobulin product switches. Twelve reactions were recorded, none of which required admission to hospital, one patient was treated with oral corticosteroids, the others required either no treatment or treatment with oral antihistamines. This review of immunoglobulin product switch reactions gives a clearer indication regarding the safety of product switching than has previously been published. ER -